Quest Diagnostics (DGX) Tops Q1 EPS by 5c
Quest Diagnostics (NYSE: DGX) reported Q1 EPS of $3.76, $0.05 better than the analyst estimate of $3.71. Revenue for the quarter came in at $2.72 billion versus the consensus estimate of $2.64 billion.
The company updates its outlook for the first half of 2021 as follows:
Updated Outlook | Previous Outlook | ||||||
Low | High | Low | High | ||||
Net revenues | $5.00 billion | $5.20 billion | $4.85 billion | $5.15 billion | |||
Net revenues increase | 37.0% | 42.5% | 32.9% | 41.1% | |||
Reported diluted EPS | $7.51 | $8.01 | $5.07 | $6.07 | |||
Adjusted diluted EPS | $6.30 | $6.80 | $5.90 | $6.90 | |||
Cash provided by operations | At least $1 billion | At least $800 million | |||||
Capital expenditures | Approximately $200 million | Approximately $200 million | |||||
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.